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Cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) 
play an important role in the first pass metabolism thereby limits 
the oral bioavailability of many clinically important and frequently 
prescribed drugs. The absolute oral bioavailability of saquinavir is 
very low (i. e. 4%) due to its extensive first pass metabolism by 
the major metabolizing isozyme CYP3A4 and it is also a substrate 
of P-gp. Pomegranate juice (PGJ) was known to be a modulator 
of CYP3A4 and P-gp. Therefore, the aim of this study was to 
evaluate the influence of PGJ on the pharmacokinetics (PK) of 
saquinavir in wistar rats and on the P-gp mediated intestinal 
transport of saquinavir in everted gut sacs ex vivo.  Rats were 
treated orally with saquinavir (100mg/kg) alone and in 
combination with PGJ (0.5, 1.0 and 2.0mL/200g, BW) for 15 
consecutive days. Blood samples were collected on 1st day in 
single dose pharmacokinetic study (SDS) and on 15th day in 
multiple dose pharmacokinetic study (MDS). The peak plasma 
concentration (Cmax) and area under the plasma concentration-
time curve (AUC0-24) of saquinavir was increased with PGJ in SDS 
(p<0.001) may be due to inhibition of CYP3A4 and P-gp. But 
interestingly, the Cmax and AUC0-24 of saquinavir was decreased 
significantly with PGJ in MDS. This is may be due to induction of 
CYP3A4. The transport of saquinavir was increased in presence of 
PGJ and known P-gp inhibitors (Verapamil, Ketoconazole and 
Quinindine) across the rat everted gut sacs ex vivo. The present 
study results suggested that PGJ has both effects (inhibition, in 
SDS and induction, in MDS) on CYP3A4-mediated saquinavir 
metabolism in vivo and inhibitory effect on the P-gp mediated 
intestinal transport of saquinavir ex vivo. Further studies are 
needed to confirm this interaction at cellular level using cell lines 
and in humans. 
 




Oral bioavailability of pharmacologically 
effective drugs is often limited by first-pass 
metabolism. P-glycoprotein (P-gp) and cyto-
chrome P450 (CYP) enzymes play an important 
role in limiting the bioavailability (BA) of orally 
administered drugs (Wahajuddin et al., 2014; 
Neirinckx et al., 2010; Wacher et al., 1998). 
Incomplete oral BA could be due to poor intes-
tinal absorption caused by P-gp or metabolism 
by CYP enzymes in the intestinal membrane or 
within the gastrointestinal (GI) lumen, or 
presystemic hepatic extraction (Letendre et al., 
2004; Martin et al., 2002; Kenneth et al., 1997).  
 
 
Figure 1. Structure of Saquinavir Mesylate 
 
Saquinavir mesylate (Figure 1) is an 
antiretroviral protease inhibitor, used for the 
treatment of human immunodeficiency virus 
(HIV) infection and it was the first protease 
inhibitor approved by the Food and drug 
administration (Brian et al., 2013; Dan et al., 
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2012; Joseph et al., 2009). It undergoes 
extensive first-pass metabolism by CYP3A4 in 
the gastrointestinal tract (GIT) and the liver. It 
is a substrate of P-gp and CYP3A4; these two 
systems critically limit its bioavailability 
(Doherty et al., 2002; Hall et al., 1999; Eagling et 
al., 1997; Doherty et al., 1997). Only about 0.7% 
of an oral dose will reach the systemic 
circulation when saquinavir is taken without 
food (Kupferschmidt et al., 1998) and 4% when 
taken with food (Noble et al., 1996).  The low 
bioavailability is thought to be due to a 
combination of incomplete absorption and 
extensive first-pass metabolism. 
Pomegranate (Punica granatum L.) is an 
edible fruit that is consumed fresh and in 
processed forms, such as juice, wines, and 
extracts. Pomegranate has been used for 
centuries in ancient cultures for its medicinal 
purposes, and numerous studies have suggested 
its health effects (Basu et al., 2009; Jurenka et al., 
2008). The pomegranate juice was composed of 
fructose (g/100g) 6.83±0.50; glucose (g/100g) 
6.66±0.44; sucrose (g/100g) 0.00±0.00; sorbitol 
(g/100g) 0.00±0.01; acidity (g/100 g as citric 
acid) 1.25±0.32; citric acid (g/100 g) 1.19±0.30; 
malic acid (g/100g) 0.065±0.034; tartaric acid 
(g/100g) 0.00±0.00; isocitric acid (mg/kg) 
63±21; potassium (mg/kg) 2320±400; proline 
(mg/kg) 7±5; formol value [milliequivalents/ 





side (Krueger et al., 2012). Pomegranate juice 
has been proposed as an anti-HIV-1 (Neurath 
et al., 2005), antioxidant (Michael et al., 2005), 
chemopreventive, chemotherapeutic (Bell et al., 
2008) anti-atherosclerotic and anti-
inflammatory agent (Lansky et al., 2007). 
Pomegranate juice was also reported as 
modulator of CYP3A4 (Farkas et al., 2007; 
Hidaka et al., 2005), CYP2C9 (Nagata et al., 2002) 
and CYP1A2 (Faria et al., 2007). However, 
whether the repeated                    co-
administration of pomegranate juice could alter 
the pharmacokinetics of saquinavir or not is 
still unknown. Therefore, the aim of this study 
was to evaluate the influence of PGJ on the   
pharmacokinetics  (PK)   of  saquinavir  in  
wistar rats and on the P-gp mediated intestinal 
transport of saquinavir in everted gut sacs ex 
vivo.   
 
MATERIALS AND METHODS  
Drugs and chemicals 
Saquinavir was gifted by Manus Aktteva 
Biopharma LLP (Ahmedabad, India). Pome-
granate fresh fruits were purchased from local 
market and made juice before administration. 
Ketoconazole, quinidine and verapamil were 
obtained from Mylan Pharmaceuticals Ltd and 
Sipra Labs Ltd (Hyderabad, India) respectively. 
Acetonitrile, water of high-performance liquid 
chromatography (HPLC) grade, sodium carbo-
xymethyl cellulose (SCMC) were purchased 
from Finar chemicals Ltd (Ahmedabad, India).  
All other chemicals and reagents used were of 
analytical grade.  
 
Experimental Animals 
Animal experiments were performed 
after the protocols approved by the animal 
ethics committee of KVSR Siddhartha           
College of Pharmaceutical Sciences (SCOPS), 
Vijayawada, India. KVSR SCOPS is registered 
(993/a/06/CPCSEA) by the Committee for 
the Purpose of Control and Supervision of 
Experiments on Animals (CPCSEA), Govt. of 
India. Male wistar rats (180-220g) were procured 
from Mahaveer Enterprises, Hyderabad, India. 
Animals were housed six per cage, fed with 
standard pellet diet (Hindustan Lever, India) 
and water ad libitum. Animals were kept under 
standard laboratory conditions (12/12h light/ 
darkness, 25±2°C, and 50-60% humidity) before 
and during the experiment. 
 
Experimental Protocol  
The study was divided into three 
experiments as it has been described previously 
by Sridhar et al. (2014) and Ravindra et al. 
(2013). First two experiments are single dose 
pharmacokinetic study (SDS) and multiple dose 
pharmacokinetic study (MDS) in vivo. The third 
experiment was conducted on rat everted gut 
sacs to determine the role of P-gp in the 
transport of saquinavir ex vivo. The doses of 
saquinavir and pomegranate juice were selected 
based upon the observations from the earlier 
experiments. 
Sridhar Vemulapalli 
Volume 27 Issue 3 (2016) 154 
Effect of pomegranate juice on the 
pharmacokinetics of saquinavir in vivo 
(SDS and MDS) 
Wistar rats were randomly divided into 
four groups of six animals in each group. The 
rats were treated orally with the following drugs 
once daily for 15 consecutive days:  
Group I: Saquinavir (100mg/kg); Group 
II: Pomegranate juice (0.5mL/200g BW.) + 
Saquinavir (100mg/kg); Group III: Pomegranate 
juice (1mL/200g BW) + Saquinavir (100mg/kg); 
Group IV: Pomegranate juice (2mL/200g BW) 
+ Saquinavir (100mg/kg). 
After treatment, 150μL blood samples 
were collected in citrated eppendorf tubes 
(Tarsons, Kolkata, India) from retro-orbital 
venous plexus (Shih et al., 2005) at 1.0, 2.0,             
2.5, 3.0, 3.5, 4.0, 4.5, 6.0, 8.0, 10.0 12.0 and 
24.0h under slight ether anesthesia on the                 
1st day in SDS and on the 15th day in MDS.   
The blood samples were centrifuged (Remi,               
R- 4C Compact model, Mumbai, India) at            
6000 rpm for 10min and plasma stored                    
at -20°C (Remi -20°C freezer, India) until 
analysis.   
 
Extraction of saquinavir from plasma 
The liquid–liquid extraction procedure 
was used to extract saquinavir from the rat 
plasma by the method described by Shriram et 
al. (2007) and Harumi et al. (2001). To an 
aliquot of 10µL plasma, 250µL of sodium 
hydroxide (0.1N) was added and pH adjusted 
to 10 with hydrochloric acid. The mixture was 
vortex-mixed for 2min on a REMI vortex 
mixer (Mumbai, India) and to this 4mL of 
extraction solvent (Methyl tertiary butyl ether: 
dichloromethane (90:10, v/v)) was added and 
vortexed for 10min. After centrifugation at 
6000 rpm for 5min, the supernatant (1mL) was 
dried under gentle stream of nitrogen at 40°C. 
The dry residue was reconstituted in 200μL of 
the mobile phase, then vortex-mixed. A 20-μL 
aliquot of the resulting solution was injected 
onto high performance liquid chromatography 
(HPLC) system for analysis. 
 
Determination of Saquinavir by HPLC  
Saquinavir concentrations in plasma 
were estimated by reverse phase-HPLC (RP-
HPLC) as it has been described previously by 
Huy et al. (1997) and Frappier et al. (1998) with 
minor modification. A Shimazdu HPLC system 
consisted of a pump (LC-20AT VP), C18 
column (ODS Thermo Hypersil, 150x4.6mm, 
5.0μm, Thermo Electron Corp, USA) and a 
dual wavelength UV-visible detector (SPD-10A 
VP). LC solution software was used to collect 
and process the data. The composition of the 
mobile phase was acetonitrile: water (50:50, 
v/v). The mobile phase was vacuum-filtered 
through 0.45μm nylon membranes filters, and 
degassed by ultrasonication for 20min before 
use. The mobile phase flow was set at 
1.0mL/min and the injection volume was 
20μL.  After equilibration with the solvent to 
obtain a stable baseline, aliquots of samples 
were injected. The total run time was set at 
5min. The absorbance of the eluent was 
monitored at 240nm. All the analyses were 
performed at 25.0±0.5°C. 
 
Preparation of stock and standard 
solutions 
Stock solution (100µg/mL) of saquinavir 
was prepared by dissolving the appropriate 
amount of saquinavir in methanol-water (50:50, 
v/v) and stored at -20°C until analysis. The 
calibration standards were prepared by dilution 
of the stock solutions with blank (drug-free) 
plasma to obtain the desired concentrations 
ranges of 0.5-20µg/mL. An aliquot of 20µL 
was injected onto the HPLC system and the 
retention times for plasma and saquinavir were 
obtained at 1.287 and 3.703min, respectively 
(Figure 2).  
 
Effect of pomegranate juice on the P-gp 
mediated transport of saquinavir ex 
vivo  
Everted sacs of rat ileum were prepared 
using a method described before by Ravindra et 
al. (2013) and Sridhar et al. (2014) in our 
laboratory. Male wistar rats weighing about 
180-200g were deprived of food for 1 day 
before the experiments, with double-distilled 
water available ad libitum. The rats were 
anesthetized with ether and the distal ileum of 
the rat intestine (approximately 10cm each) was 
dissected. Each intestinal segment was 
immediately rinsed in ice-cold Krebs-Ringer-
Hensleit (KRH) bicarbonate buffer (7.8g NaCl, 
0.35g KCl, 0.37g CaCl2, 1.37g NaHCO3, 0.32g 
NaH2PO4,  0.02g MgCl2,  1.4g glucose, pH 6.8).  
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The intestinal segments were everted using a 
stain less steel rod and one end was ligated. The 
open end of the everted sac was ligated after 
the insertion of a polyethylene tube. After the 
everted sac was filled with 1mL of KRH buffer, 
placed in 30mL of KRH buffer gassed with 
O2/CO2 (95:5) at 37°C for 30min. About 
100μg/mL of saquinavir was added to the 
mucosal side and aliquots (150μL) of serosal 
fluid were collected at 10, 20, 30, 40, 50 and 
60min. The same volume of buffer was 
replaced at each time point. The intestinal 
absorption of saquinavir in the absence and 
presence of pomegranate juice and standard P-
gp and CYP3A4 inhibitors (verapamil, 
ketoconazole and quinidine, 50μg/mL) was 
also determined by using the above method. At 
the end of incubation all samples were 
centrifuged at 3500rpm for 10min and 
supernatants was used RP-HPLC analysis.  
 
Calculation of pharmacokinetic parameters 
The plasma concentrations versus time 
data for saquinavir obtained from each individual 
rat were submitted to a non-compartmental 
pharmacokinetic analysis using Thermo Kinetica 
(Version 5.1, Thermo Electron Corporation, 
USA) pharmacokinetics fitting software to 
calculate the model-independent pharmaco-
kinetic parameters. These parameters were the 
area under the plasma concentration-time curve 
(AUC) from time zero to the last sampling time 
(AUC0-t), AUC from time zero to infinite 
(AUC0-α), apparent terminal half-life (t1/2), 
clearance (CL/F), apparent volume of distri-
bution (Vz/F), apparent volume of distribution 
at steady state (Vss) and mean residence time 
(MRT). Maximum plasma concentrations (Cmax) 
and times to achieve maximum plasma concen-
trations (Tmax) were obtained directly from the 





Figure 2. Representative Chromatograms of (a) Plasma blank (1.287); (b) Saquinavir 10μg/mL 
(3.701); (c) Plasma + Saquinavir 1μg/mL and (d) plasma sample from a rat receiving 100mg/kg 
saquinavir monitored at 240nm. 
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Statistical analysis  
All statistics were calculated using Graph 
Pad Prism 5.0 software (San Diego, CA, USA). 
Pharmacokinetic parameters and plasma 
concentrations of saquinavir for groups were 
compared using two-way ANOVA followed by 
Bonferroni post-tests to compare to each 
column to column. Ex vivo data analysed by 
one-way ANOVA followed by Dunnett’s post 
hoc test. The p value less than 0.05 were 
considered significant. 
 
RESULTS  AND  DISCUSSION   
Effect of pomegranate juice on the 
pharmacokinetics of saquinavir in SDS 
The plasma concentration-time profiles 
of saquinavir after the oral administration of 
the saquinavir alone (100mg/kg) and in 
combination with pomegranate juice (0.5, 1.0, 
and 2.0mL/200g BW) in SDS (Figure 3(A)). 
When saquinavir was co-administered with 
pomegranate juice, the plasma concentrations 
of saquinavir were significantly increased 
compared to the saquinavir alone group (Fig. 
3A). The mean pharmacokinetic parameters of 
saquinavir in plasma (Table I). The Cmax of 
saquinavir was significantly increased from 
5.852±1.282 to 10.205±1.645 and 8.473±1.568 
μg/mL when co-administered with pomegranate 
juice 0.5mL and 1.0mL/200g, respectively.            
The AUC0-∞ of saquinavir was increased              
from 21.591±3.155 to 49.741±4.620 (with 
pomegranate juice 0.5mL), and 53.936±3.120ìg. 
h/mL (with pomegranate juice 2.0mL). The t1/2 
of saquinavir after pomegranate juice treatment 
was longer than saquinavir alone group 
(p<0.01). The MRT of saquinavir was increased 
from 4.683±0.841 to 8.423±2.312h when co-
administered with pomegranate juice (2mL/ 
200g). The CL/F, VZ/F, and Vss/F of saquinavir 
were significantly decreased by pomegranate 
juice. 
 
Effect of pomegranate juice on the 
pharmacokinetics of saquinavir in MDS 
Figure 3B shows the mean plasma 
concentration-time data obtained after oral 
administration of saquinavir (100mg/kg) alone 
and in combination with pomegranate juice for 
15 consecutive days in rats. Plasma concen-
trations of saquinavir were significantly 
decreased in the rats treated with pomegranate 
juice. The Cmax of saquinavir decreased 
significantly from 12.352±1.361 to 7.595±2.624 
(with 1.0mL, pomegranate juice) and 
8.336±1.582 μg/mL (with 2.0mL, pomegranate 
juice). Pomegranate juice co-administration for 
15 consecutive days significantly decreased the 
AUC0-∞ of saquinavir from 98.091±5.260 to 
59.661±4.281 (with 0.5mL, pomegranate juice) 
and 64.217±5.362μg. h/mL (with 2.0mL, 
pomegranate juice). The t1/2 of saquinavir was 
shorter when used with pomegranate juice.  
  
 
Figure 3. Mean plasma concentration–time profiles of saquinavir (100 mg/kg) following an oral 
administration of saquinavir to rats with or without pomegranate juice (A) on 1st day; (B) on 15th 
day (n=6). (●) Control (saquinavir alone), ( ) with pomegranate juice (0.5 mL/200g b.w.), (▲) 
with pomegranate juice (1 mL/200g b.w.), (▼) with pomegranate juice (2 mL/200g b.w.). All 
values are Mean ± SD. Bars represent the standard deviation. *p < 0.001, when compared to 
saquinavir control group. SQV, Saquinavir; PGJ, Pomegranate juice. (Two-way ANOVA followed 
by Bonferroni post-tests to compare to each column to column). 
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The saquinavir t1/2 was decreased from 
4.295±1.211 to 2.912±0.648 h (with 0.5mL, 
pomegranate juice). The MRT of saquinavir 
also reduced from 7.851±1.482 to 
6.055±1.340h with co-administration of 0.5mL 
of pomegranate juice. A significant difference 
was not observed in the apparent total body 
clearance of saquinavir compared to saquinavir 
control group (Table II). 
Effect of pomegranate juice on the 
saquinavir absorption ex vivo 
It is known that saquinavir is transported 
by P-gp present in the intestinal epithelium. To 
determine the influence of pomegranate juice 
on the P-gp mediated saquinavir transport, 
studied its transport activity in-vitro using 
everted gut sacs. The transport of saquinavir 
was  increased in addition of pomegranate juice 
 
 
Figure 4. The transport of saquinavir (100μg/mL) from mucosal to serosal side in the absence and 
presence of verapamil, quinidine, ketoconazole (50 μg/mL) and pomegranate juice (0.5mL/sac). 
SQV: Saquinavir; VER: Verapamil; QDN: Quinidine; KTZ: Ketoconazole; PGJ, Pomegranate 
juice. The data represent the mean ±S.D. (n=3). *p<0.001significantly different compared to 
saquinavir group. 
 
Table I. Pharmacokinetic parameters of saquinavir after the oral administration of saquinavir  
(100mg/kg) to rats in the presence or absence of pomegranate juice (0.5, 1 and 2mL/200g) on 1st day (n 
= 6). 
 

























































SQV, Saquinavir; PGJ, Pomegranate juice; AUC0-24, Area under the plasma concentration-time curve from 0h 
to 24h; AUC0-∞, area under the plasma concentration-time curve from 0 h to infinity; Cmax, peak plasma 
concentration; Tmax, time to reach peak plasma concentration; t1/2, terminal half-life; MRT, mean residence 
time; CL/F, apparent total body clearance or oral clearance; Vz/F, apparent volume of distribution; Vss, 
apparent volume of distribution at steady state. All values are Mean ± SD. ***p < 0.001, **p < 0.01, *p < 0.05, 
NSp > 0.05 when compared to rasagiline alone group (Two-way ANOVA followed by Bonferroni post-tests 
to compare to each column to column). 
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and P-gp inhibitors (verapamil, ketoconazole 
and quinidine) to the mucosal compartment 
with time in all groups studied (Table III). 
Saquinavir transport was significantly enhanced 
from 4.561±0.526 to 9.913±2.361 (with 
verapamil), 10.426±1.421 (with ketoconazole), 
8.521±2.063 (with quinidine) and 8.575±1.631 
(with pomegranate juice) at the end of 1h 
incubation period. These results suggested that 
the absorption of saquinavir was increased by 
pomegranate juice may be due to P-gp 
inhibition (Figure 4).  
Absorption is a complex multifactorial 
phase in pharmacokinetics, and one of the 
determinants of the clinical outcomes of drug 
therapy. One of the major obstacles to drug 
absorption is intestinal metabolism by CYP3A4 
(Huang et al., 2008; Yang et al., 2007; Beverly et 
al., 2006). CYP3A4 is the most important drug-
metabolizing enzyme and metabolizes many 
Table II. Pharmacokinetic parameters of saquinavir after the oral administration of saquinavir    
(100mg/kg) to rats in the presence or absence of pomegranate juice (0.5, 1 and 2mL/200g) on 15th 
day (n = 6). 
 

























































SQV, Saquinavir; PGJ, Pomegranate juice; AUC0-24, Area under the plasma concentration-time curve from 0h 
to 24h; AUC0-∞, area under the plasma concentration-time curve from 0h to infinity; Cmax, peak plasma 
concentration; Tmax, time to reach peak plasma concentration; t1/2, terminal half-life; MRT, mean residence 
time; CL/F, apparent total body clearance or oral clearance; Vz/F, apparent volume of distribution; Vss, 
apparent volume of distribution at steady state. All values are Mean ± SD. ***p < 0.001, **p < 0.01, *p < 0.05, 
NSp > 0.05 when compared to rasagiline alone group (Two-way ANOVA followed by Bonferroni post-tests 
to compare to each column to column). 
 
Table III. Transport of saquinavir from the mucosal to serosal side with or without verapamil, 
ketoconazole, quinidine (50µg/mL) and pomegranate juice (0.5mL/sac) using everted gut sacs ex 
vivo (n=3). 
 












































SQV, Saquinavir; VER, Verapamil; KTZ, Ketoconazole; QDN, Quinidine; PGJ, Pomegranate juice. All 
values are Mean ± SD. ***p < 0.001, **p < 0.01, *p < 0.05, NSp > 0.05 when compared to rasagiline alone group 
(Two-way ANOVA followed by Bonferroni post-tests to compare to each column to column). 
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drugs. It is most abundant on the apex of 
mature enterocytes and is mainly situated in the 
villous tips of the upper and middle third of the 
intestine (Genser et al., 2008; Undevia et al., 
2005). The enzymes of CYP3A4 expressed in 
liver and intestine are structurally identical. In 
addition to CYP3A4 in the intestinal 
epithelium, an efflux transporter (P-gp) can 
play a role in altering the bioavailability and 
pharmacokinetic profiles of substrates (Ho et 
al., 2005; Chandra et al., 2004). P-gp mediated 
efflux across the apical membrane (facing the 
intestinal lumen) and CYP3A4-mediated 
metabolism in the endoplasmic reticulum of 
enterocytes can affect the rate and amount of 
compound that diffuses across the basolateral 
membrane and enters the bloodstream. 
CYP3A4 shares many substrates with P-gp 
(Paine et al., 2006; Paine et al., 1997). 
Saquinavir is one of the most widely 
prescribed agents in the treatment of acquired 
immunodeficiency syndrome (AIDS), but the 
oral bioavailability is low (Holladay et al., 2001; 
Williams et al., 1992). One contributing factor 
to the low and variable oral bioavailability of 
saquinavir is extensive and variable first-pass 
metabolism by CYP3A4. The relative contri-
butions by hepatic and intestinal CYP3A4 to 
the first-pass metabolism of saquinavir are not 
known (Stephane et al., 2004). Saquinavir is 
substrate of CYP3A4 and P-gp thereby inhibition 
of CYP3A4-mediated first-pass metabolism is 
the presumed primary mechanism underlying 
the significant increase in saquinavir systemic 
exposure when saquinavir is administered in 
combination with the known potent CYP3A4 
inhibitors. Pazopanib is an inhibitor of CYP3A4 
and vemurafenib is a P-gp inhibitor, which 
increased the serum concentrations of saquinavir 
when given concomitantly, thus increased the 
risk of drug toxicity and proarrhythmic effects 
(Eberl et al., 2007; Lee et al., 1998). Many drug 
interactions have been reported between 
saquinavir and CYP3A4 and P-gp inhibitors 
(azithromycin, sorafenib, ritonavir, nelfinavir, 
ketoconazole, calcium channel blockers, 
telithromycin and quinidine).   
Pomegranate juice is known to be a 
potent inhibitor of CYP3A4. Swathi et al. 
(2012) reported that pomegranate juice 
increased the Cmax of nitrendipine from 1.93 ± 
0.18 to 7.92 ± 1.39 (µg/mL) and AUCtotal from 
10.32 ± 0.77 to 51.57 ± 4.56 (µg/h/mL) due to 
inhibition of CYP3A4-mediated nitrendipine 
metabolism in rats. In another study, the Cmax 
and AUC of carbamazepine (CYP3A4 substrate) 
were significantly increased by pomegranate 
juice co-administration in rats (Muneaki et al., 
2005). The Cmax of buspirone (CYP3A4 substrate) 
was increased by 4.998-fold, AUC0-∞ increased 
by 5.109-fold. AUC0-24 increased by 4.892-fold, 
t½ increased by 1.304-fold and Tmax increased 
by 1.197-folds after pretreatment with pome-
granate juice (Shravan et al., 2011). In the 
present study, the Cmax of saquinavir was 
increased by 1.734-fold (with 0.5 mL, 
pomegranate juice) and 1.447-folds (with 1.0 
mL, pomegranate juice) when saquinavir was 
co-administered with pomegranate juice on the 
1st day. The AUC0-24 of saquinavir was also 
increased by 2.370-folds with pomegranate 
juice treatment. The intestinal transport of 
saquinavir was also significantly increased by 
1.880-folds with pomegranate in the everted 
gut sacs ex vivo. The present study results 
suggested that pomegranate juice enhanced the 
systemic exposure of saquinavir by inhibition of 
CYP3A4-mediated metabolism in SDS and P-
gp mediated efflux ex vivo.  
Adukondalu et al. (2010) reported that 
pomegranate juice has induction effect on the 
CYP3A4 enzymes thereby decreased the 
plasma concentrations of carbamazepine in 
rats. In the present study, pomegranate juice 
also decreased the Cmax and AUC of saquinavir 
when co-administered with saquinavir for 15 
consecutive days (p<0.01). This is may be due 
to induction of CYP3A4-mediated saquinavir 
metabolism by pomegranate juice.  
 
CONCLUSION  
The present study results suggested that 
PGJ has both effects (inhibition, in SDS and 
induction, in MDS) on CYP3A4-mediated 
saquinavir metabolism in vivo and inhibitory 
effect on the P-gp mediated intestinal transport 
of saquinavir ex vivo. Further studies are needed 
to identify the active components in 
pomegranate juice and evaluate their effects on 
CYP3A4 and P-gp over expressed cell lines and 
in humans.   
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